Oct. 24, 2011
/PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that SPX-106T (the combination of D-tagatose and SPX-106) reduced dyslipidemia in new studies of apolipoprotein E-deficient mice and Syrian Golden hamsters. This finding corroborates data obtained in LDL receptor-deficient mice (see Spherix press release of
September 8, 2011
). Additionally, a new study in rats demonstrates that D-tagatose inhibits fructose absorption in the gastrointestinal tract, providing further insight into the mechanism of action of SPX-106T.
"Successful results in additional animal models increases our confidence going into human clinical trials with SPX-106T next spring," noted Dr.
, CEO of Spherix.
In a poster at the American Association of Pharmaceutical Scientists (AAPS) National Meeting, Spherix summarizes results obtained with SPX-106T in two strains of genetically engineered mice prone to dyslipidemia. SPX-106T significantly reduced VLDL and LDL cholesterol in LDL receptor-deficient mice fed normal chow. In apolipoprotein E-deficient mice fed a Western (high fat/high carbohydrate) diet, SPX-106T significantly reduced serum cholesterol by 30% (-307 mg/dl; p<0.05), prevented body weight gain (p<0.05), and significantly reduced the amount of subcutaneous, retroperitoneal, and epididymal fat (77, 90, 85% reductions, respectively, p<0.01) (see photo). SPX-106T did not affect the weight of other organs (heart, spleen, etc.). A recent range-finding dose study in hamsters fed the same Western diet and given SPX-106T provided evidence that the combination was effective in reducing serum triglycerides.
"An important new element in our work with SPX-106T is that we are now performing studies designed specifically to test therapy in diet-induced lipidemia, using dosing and timing information derived from the studies completed a few months ago in LDL receptor-deficient mice," said Dr.
, President of Spherix.
The poster is authored by Dr. Kruger; Dr. Lodder; Dr.
, Science Consultant; and Dr.
A. Wallace Hayes
, Principal Advisor. It will be presented at the AAPS National Meeting from
to 12 noon local time on
Wednesday, October 26, 2011
. The Meeting is being held at the Walter E. Washington Convention Center in
October 23 through 27
Spherix also demonstrates that D-tagatose blocks absorption of fructose through the gut. D-tagatose administered to Sprague-Daley rats in ascending doses was given in combination with 14C-fructose and blood levels of 14C-fructose were quantified over 60 minutes. Results showed that D-tagatose significantly decreased the amount of plasma 14C-fructose up to 30% (p<0.05). The resulting decrease in systemically absorbed fructose is a mechanism by which D-tagatose can effectively reduce diet-induced dyslipidemia.